Research ArticleGout
Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Jung Sun Lee, Jebum Won, Oh Chan Kwon, Seung Soo Lee, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong
The Journal of Rheumatology May 2019, 46 (5) 527-531; DOI: https://doi.org/10.3899/jrheum.180761
Jung Sun Lee
From the Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center; Department of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul,
Korea.
Jebum Won
Oh Chan Kwon
Seung Soo Lee
Ji Seon Oh
Yong-Gil Kim
Chang-Keun Lee
Bin Yoo
REFERENCES
- 1.↵
- 2.↵
- 3.↵
- Lim DH,
- Oh JS,
- Ahn SM,
- Hong S,
- Kim YG,
- Lee CK,
- et al.
- 4.↵
- National Institutes of Health and LiverTox
- 5.↵
- National Institutes of Health and LiverTox
- 6.↵
- 7.↵
- Bohm M,
- Vuppalanchi R,
- Chalasani N;
- Drug-Induced Liver Injury Network
- 8.↵Febuxostat: hepatic failure. Prescrire Int 2013;22:297.
- 9.↵
- 10.↵
- 11.↵
- 12.↵
- 13.↵
- Neogi T,
- Jansen TL,
- Dalbeth N,
- Fransen J,
- Schumacher HR,
- Berendsen D,
- et al.
- 14.↵
- 15.↵
- Lewis JH,
- Mortensen ME,
- Zweig S,
- Fusco MJ,
- Medoff JR,
- Belder R;
- Pravastatin in Chronic Liver Disease Study Investigators
- 16.↵
- Sharma P,
- Tyagi P,
- Singla V,
- Bansal N,
- Kumar A,
- Arora A
- 17.↵
- Tang W,
- Mu J,
- Chen QI,
- Li X,
- Liu H
- 18.↵
- 19.↵
- 20.↵
- 21.↵
- Iryna K,
- Helen M,
- Elena S
- 22.↵
- 23.↵
- National Institutes of Health and LiverTox
- 24.↵
- Abbott CE,
- Xu R,
- Sigal SH
- 25.↵
- Gautam M,
- Islam T,
- Shaikh N,
- Singh S
- 26.↵
- Slobodnick A,
- Shah B,
- Krasnokutsky S,
- Pillinger MH
- 27.↵
In this issue
The Journal of Rheumatology
Vol. 46, Issue 5
1 May 2019
Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Jung Sun Lee, Jebum Won, Oh Chan Kwon, Seung Soo Lee, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong
The Journal of Rheumatology May 2019, 46 (5) 527-531; DOI: 10.3899/jrheum.180761